Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice

Ítems similars

• Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical Practice
  per: Costarelli, Silvia, et al.
  Publicat: (2016)
• Durability of lopinavir/ritonavir dual-therapies in individuals with viral load <50 copies/mL in the observational setting
  per: Gianotti, Nicola, et al.
  Publicat: (2014)
• Determinants of use of the fixed dose combination emtricitabine/rilpivirine/tenofovir (Eviplera) in HIV-infected persons receiving care in Italy
  per: Cozzi-Lepri, Alessandro, et al.
  Publicat: (2014)
• Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation Cohort
  per: d’Arminio Monforte, Antonella, et al.
  Publicat: (2016)
• Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation Cohort.
  per: Antonella d'Arminio Monforte, et al.
  Publicat: (2016-01-01)